Proteoglycan Mimetics For Enhanced Wound Healing Angiogenesis And Vascular Repair

Pro-angiogenic scaffold Accelerates ischemic wound healing Prevents rapid collagen matrix degradation Limits systematic exposure to VEGF Can be delivered via catheter post balloon angioplasty

Tissue regeneration Atherosclerotic conditions Enhanced wound healing and vascular repair

Current therapies for treating wounds and ischemia often use growth factors, such as vascular endothelial growth factor (VEGF) and stents promote revascularization and blood vessel growth and prevent closure of a blood vessel. The clinical success of such growth factor therapies for wounds, however, have been limited dude to overexpression of matrix metalloproteases (MMPs) after injury which can degrade and inactivate the growth factors. Additionally, while stents provide structural support and are effective in preventing artery closure short term, they are ineffective in preventing restenosis (even with the introduction of drug-eluting stents (DESs)) long term. Researchers at the University of California, Davis We have developed proteoglycan mimetics that alter the extracellular environment to promote local vascular repair and wound healing without the use of stents. This method utilizes a combination of collagen-binding and integrin-binding peptides and a glycan to target and enhance endothelial cell and endothelial progenitor cell capture. The pro-angiogenic scaffold supports tissue regeneration while limiting systemic exposure to VEGF, suppressing platelet binding and inflammation while promoting reendothelialization. These mimetics can potentially prevent rapid collagen matrix degradation and accelerate ischemic wound healing while preventing long-term complications including thrombosis, scaring and a foreign body response. removing the need for stents.

Additional Technologies by these Inventors

• Ligands for Alpha-4-Beta-1 Integrin
• Three-Dimensional Cell Adhesion Matrix
• A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
• Functional Illumination in Living Cells
• Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
• Sutureless Anastomosis Device
• Nanoporphyrin Nanoparticles for Combination Phototherapy and Drug Delivery to Infantile Hemangiomas
• Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
• PVA Nanocarrier System for Controlled Drug Delivery
• Site-Specific Ligation and Compound Conjugation to Existing Antibodies
• Novel Solid Tumor Chemodrug LLS2
• High Throughput Label-Free One-Bead-One-Compound (OBOC) Screening Assay
• Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices

Tech ID/UC Case

29598/2018-492-0

Related Cases

2018-492-0

USA